atomoxetine

Last reviewed 01/2018

  • atomoxetine licensed for the treatment of ADHD in children 6 years and older and in adolescents, under specialist supervision
    • a selective noradrenaline reuptake inhibitor, although the precise mechanism by which it works on ADHD is unknown
    • common adverse effects of treatment include abdominal pain, decreased appetite, nausea and vomiting, early morning awakening, irritability and mood swings. Increased heart rate and small increases in blood pressure were observed in clinical trials. For full details of adverse effects and contraindications, see the Summary of Product Characteristics

The Summary of Product Characteristics must be consulted before prescribing this drug.

Reference:

  1. NICE (March 2006). Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents

Related pages:

attention deficit hyperactivity disorder

monitoring side effects and the potential for misuse of ADHD drug treatment in children, young people and adults

duration, discontinuation and continuity of ADHD treatment

atomoxetine and antidepressants